Springworks Therapeutics (SWTX) just unveiled an announcement.
SpringWorks Therapeutics, Inc. has enhanced its Board of Directors by appointing Martin Mackay as an independent Class II director, with his term set to conclude at the 2027 annual stockholders’ meeting. Although not assigned to any Board committees, Mackay will receive standard compensation as per the company’s policy, including both cash and equity in the form of stock options and restricted stock units. His appointment, which aligns with the company’s governance guidelines and Nasdaq standards, was publicly announced with no disclosed conflicts of interest.
Find detailed analytics on SWTX stock on TipRanks’ Stock Analysis page.
